Nemaura Medical Inc. (NMRD)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 26.37 Million USD | 21.92% |
| 2022 | 21.63 Million USD | -19.52% |
| 2021 | 26.88 Million USD | 961.39% |
| 2020 | 2.53 Million USD | -0.15% |
| 2019 | 2.53 Million USD | 18.3% |
| 2018 | 2.14 Million USD | 5.36% |
| 2017 | 2.03 Million USD | -0.91% |
| 2016 | 2.05 Million USD | 12.21% |
| 2015 | 1.83 Million USD | 9.23% |
| 2014 | 1.67 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 22.82 Million USD | -13.46% |
| 2024 Q3 | 22.99 Million USD | -7.23% |
| 2024 Q2 | 24.78 Million USD | 8.59% |
| 2023 FY | 26.37 Million USD | 21.92% |
| 2023 Q3 | 22.82 Million USD | -8.41% |
| 2023 Q1 | 23.67 Million USD | 9.42% |
| 2023 Q4 | 26.37 Million USD | 15.59% |
| 2023 Q2 | 24.91 Million USD | 5.24% |
| 2022 Q1 | 27.71 Million USD | 3.09% |
| 2022 Q4 | 21.63 Million USD | -16.95% |
| 2022 FY | 21.63 Million USD | -19.52% |
| 2022 Q3 | 26.05 Million USD | -4.33% |
| 2022 Q2 | 27.22 Million USD | -1.76% |
| 2021 Q3 | 7.31 Million USD | 6.49% |
| 2021 Q4 | 26.88 Million USD | 267.68% |
| 2021 Q1 | 6.95 Million USD | 174.7% |
| 2021 Q2 | 6.86 Million USD | -1.31% |
| 2021 FY | 26.88 Million USD | 961.39% |
| 2020 FY | 2.53 Million USD | -0.15% |
| 2020 Q4 | 2.53 Million USD | 5.62% |
| 2020 Q1 | 2.66 Million USD | 5.14% |
| 2020 Q2 | 2.5 Million USD | -6.0% |
| 2020 Q3 | 2.39 Million USD | -4.35% |
| 2019 Q3 | 2.59 Million USD | 11.13% |
| 2019 Q4 | 2.53 Million USD | -2.13% |
| 2019 Q1 | 2.45 Million USD | 14.66% |
| 2019 Q2 | 2.33 Million USD | -5.15% |
| 2019 FY | 2.53 Million USD | 18.3% |
| 2018 Q1 | 2.24 Million USD | 10.28% |
| 2018 Q2 | 2.06 Million USD | -7.89% |
| 2018 Q3 | 2.3 Million USD | 11.45% |
| 2018 Q4 | 2.14 Million USD | -6.93% |
| 2018 FY | 2.14 Million USD | 5.36% |
| 2017 Q4 | 2.03 Million USD | -5.83% |
| 2017 FY | 2.03 Million USD | -0.91% |
| 2017 Q3 | 2.16 Million USD | 2.04% |
| 2017 Q2 | 2.11 Million USD | -1.15% |
| 2017 Q1 | 2.14 Million USD | 4.32% |
| 2016 Q4 | 2.05 Million USD | -2.83% |
| 2016 Q2 | 2.1 Million USD | 11.94% |
| 2016 Q3 | 2.11 Million USD | 0.26% |
| 2016 Q1 | 1.88 Million USD | 2.89% |
| 2016 FY | 2.05 Million USD | 12.21% |
| 2015 Q2 | 1.81 Million USD | 0.46% |
| 2015 FY | 1.83 Million USD | 9.23% |
| 2015 Q3 | 1.62 Million USD | -10.51% |
| 2015 Q4 | 1.83 Million USD | 12.9% |
| 2015 Q1 | 1.8 Million USD | 7.62% |
| 2014 Q3 | 18.22 Thousand USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | 1.67 Million USD | 9093.95% |
| 2014 FY | 1.67 Million USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acutus Medical, Inc. | 54.83 Million USD | 51.9% |
| Biotricity, Inc. | 35.91 Million USD | 26.565% |
| Cell MedX Corp. | 872.57 Thousand USD | -2922.934% |
| Dynatronics Corporation | 11.78 Million USD | -123.915% |
| PetVivo Holdings, Inc. | 2.42 Million USD | -985.804% |
| RetinalGenix Technologies Inc. | 1.4 Million USD | -1776.312% |
| Sonendo, Inc. | 49.74 Million USD | 46.97% |
| Telesis Bio, Inc. | 40.87 Million USD | 35.465% |
| Talis Biomedical Corporation | 29.22 Million USD | 9.741% |
| Viveve Medical, Inc. | 10.84 Million USD | -143.177% |